300404 Boji Medical Technology
- 9.46
- -0.03-0.32%
Boji Medical Technology News
Boji Pharmaceutical (300404) Interim Report Review: Clinical business grew rapidly in the first half of the year, and there were plenty of orders in hand
Boji Pharmaceutical (300404): Rapid development of clinical business further strengthens innovative traditional Chinese medicine service capabilities
Boji Pharmaceutical (300404): Results in the first quarter of 2024 resumed high growth and rapid order growth
Boji Pharmaceutical (300404) Quarterly Report Review: Results in the first quarter of 2024 resumed high growth, and orders grew rapidly
Boji Pharmaceuticals (300404): Order growth is impressive, waiting for profit margins to improve
Boji Pharmaceutical (300404) Interim Report Review: Performance is growing steadily, orders for traditional Chinese medicine are growing rapidly
Boji Pharmaceuticals (300404): Bocai Zhongfang Guangji World
Boji Pharmaceutical (300404): Non-profit deductions increased 98% year-on-year in 2023Q1, the new policy on registration of traditional Chinese medicine helped new orders for traditional Chinese medicine increase 86%
Boji Pharmaceutical (300404) Company Review Report: Normalized Equity Incentives Show Confidence in Performance Growth
Boji Pharmaceutical (300404): A scarce listed Chinese medicine clinical CRO company
Boji Pharmaceutical (300404) Research Brief: Order growth is good in 2022, long-term growth can be expected
Boji Pharmaceutical (300404) Research and Analysis Report: Clinical service business continued to pick up in the third quarter and is expected to benefit from the rapid development of the industry in the future
Boji Pharmaceutical (300404) Quarterly Report Review: Clinical Service Business Continued to Pick Up in the Third Quarter
Boji Pharmaceutical (300404) Interim Report Commentary: 722's Impact Has Subsided and Lay Out New Drug R&D CRO+CDMO's Entire Industry Chain
Boji Pharmaceutical (300404) Annual Report and Quarterly Report Review: Breaking the trough and reversal of performance
Boji Pharmaceutical (300404) interim report review: 2017 H1 performance bottomed out and rebounded 127.37% year-on-year
Boji Pharmaceutical (300404) Annual Report Review: 2017 Q1 performance is gradually bottoming out, and future performance reversals can be expected
Review of Boji Pharmaceuticals (300404) Annual Report and Quarterly Report: CRO business has recovered significantly, and new orders added in 2017 Q1 exceeded expectations
Comment on Boji Pharmaceutical (300404) three-quarter report: revenue decline continues to narrow Q3 performance and successfully reverse losses.
[Southwest Securities] Boji Pharmaceuticals: Revenue decline continues to narrow, Q3 performance successfully reversed losses
Analysis
Price Target
No Data
No Data